drugset
Drugs / Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes
last change Dec 2025 re-read 3 minutes ago

Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes

also known as LMP-TC

Cell therapy

Developed for
post-transplant lymphoproliferative disease
Investigated by
Children's Oncology Group · National Cancer Institute (NCI)

Trials 1

today NCT02900976 · Ph 2
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02900976 Mar 2017 → Mar 2021 post-transplant lymphoproliferative disease Children's Oncology Group Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes ClinicalTrials.gov intervention name — accepted as the source's own label NCT02900976 ↗
Known as LMP-TC “third-party latent membrane protein-specific T cells (LMP-TCs)” PMID 38163318 ↗ Mar 2024
Modality Cell therapy “allogeneic LMP1/LMP2-specific cytotoxic T-lymphocytes” NCT02900976 ↗
Route Intravenous “Given IV” NCT02900976 ↗